6:11 PM
 | 
Jul 25, 2008
 |  BC Extra  |  Company News

FDA releases Actemra briefing document

An FDA briefing document released in advance of a July 29 advisory committee meeting concludes that Actemra tocilizumab from Roche (SWX:ROG) is effective for treating moderate to severely active rheumatoid arthritis (RA). The agency's Arthritis Advisory Committee is likely to...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >